Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 9/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | IDH1 | O75874 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5044256 | 1.00 | HSD17B3 (0.47) | HSD17B3P2RX4CYP11B2CYP11B1IDH1 | |
| SCHEMBL5038796 | 0.78 | HSD17B3 (0.52) | HSD17B3P2RX4CYP11B2CYP11B1 | |
| SCHEMBL5038800 | 0.78 | HSD17B3 (0.52) | HSD17B3P2RX4CYP11B2CYP11B1 | |
| SCHEMBL5044247 | 0.77 | HSD17B3 (0.46) | HSD17B3CYP11B2IDH1 | |
| SCHEMBL5044246 | 0.77 | HSD17B3 (0.46) | HSD17B3CYP11B2IDH1 | |
| SCHEMBL4047071 | 0.76 | HSD17B3 (0.70) | HSD17B3 | |
| SCHEMBL4048923 | 0.76 | HSD17B3 (0.70) | HSD17B3 | |
| SCHEMBL5044757 | 0.71 | HSD17B3 (0.60) | HSD17B3P2RX4CYP11B2CYP11B1 | |
| SCHEMBL5044763 | 0.71 | HSD17B3 (0.60) | HSD17B3P2RX4CYP11B2CYP11B1 | |
| SCHEMBL5038871 | 0.71 | HSD17B3 (0.53) | HSD17B3P2RX4CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725565-B1 | FUSED HETEROTRICYCLIC COMPOUNDS AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE 3 | BRISTOL MYERS SQUIBB CO (US) | 2013-07-03 | — | — | EP | disclosed |
| US-7378426-B2 | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050192310-A1 | Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192310-A1 | Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B1, HSD17B2 | HSD17B3 1/4885P2RX4 4866/4885CYP11B2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.